Department of Pathology, Gachon University Gil Medical Center, Incheon, Korea
1Department of General Surgery, Gachon University Gil Medical Center, Incheon, Korea
2Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea
3Department of Radiation Oncology, Gachon University Gil Medical Center, Incheon, Korea
© 2016 The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Case No. | Author | Age(yr)/Sex | Presenting symptom | Gross and histopathology | Immunohistochemistry | TNM at the initial evaluation | Treatment | Clinical outcome (follow-up period) |
---|---|---|---|---|---|---|---|---|
1 | Uchigasaki et al. (1992) [3] | 52/F | Anal ulcer and pruritus for 2 yra | Anal canal SRCC progressed from adenocarcinoma in situ of anal glands or mucinous glands (1.5 cm), Pagetoid spread (7 cm) | pCEA+ mCEA+ mucicarmine+ PAS+ D-PAS-resistant | T1N3M0, stage IIIB | Topical 5-FU cream, EB, ASR | Recurrence with systemic metastasis and died (7 mo) |
2 | Morihisa et al. (1999) [7] b | 75/F | Perianal erythema and erosion for 7 mo | Anal canal SRCC (size not described), Pagetoid spread (5 cm) | CEA+ mucicarmine+ PAS+ | N3M1, stage IV | Nephrostomy for ARF due to systemic metastasis | Systemic metastasis and died (4 mo) |
3 | Nagano et al. (1999) [8] | 46/F | Inguinal LN enlargement | Anal canal and rectal SRCC (3.5 cm), Pagetoid spread (7.5 cm) | Alcian blue+ PAS+ | T2N3M0, stage IIIB | APR, CTX (5-FU, LV) | NR (3 mo) |
4 | Naganuma et al. (2004) [9] | 85/F | Anal bleeding for 3 yr | Anal canal SRCC (unknown size of polyp, residual anal canal mass, 5 mm), Pagetoid spread (size not described) | CEA+ CA19-9+ CK20+ CK7– GCDFP-15– | N3M1, stage IV | Anal polypectomy with CTX (5-FU), RT | Systemic metastasis and died (25 mo) |
5 | Nishimura et al. (2004) [10] b | 76/F | Anal erosion and etythema for 2 yr | Anal canal SRCC (size not described), Pagetoid spread (6 cm) | CK20+ GCDFP-15- | Not availableb | APR, CTX (5-FU, cisplatin) | NR (5 mo) |
6 | Yoshitani et al. (2009) [11] | 50/M | Axillary and inguinal LN enlargement for 1 mo, erythematous perianal skin | Anal canal SRCC (size not precisely described; anal verge to dentate line), Pagetoid spread (size not described) | CK20+MUC-1+CK7- | N3M1, stage IV | CTX (bevacizumab/mFOLFOX6, FOLFIRI) | Alive with CR evaluated by PET-CT (6 mo) |
7 | Ikezawa et al. (2010) [12] | 53/M | Anal pruritus for 22 mo | Anal canal SRCC (1 cm), Pagetoid spread (2 cm) | pCEA+ CK20+ CK7– GCDFP-15– | T1N2M0, stage IIIB | APR, CTX (uracil-tegafur, LV, mFOLFOX6) | Recurrence with systemic metastasis and died (9 mo) |
8 | Ioannidis et al. (2012) [4] | 87/F | Anal discomfortness and pain for 8 mo | Anal canal SRCC (3 cm) | Not done | T2N0M0, stage II | Wide excision with chemotherapy (5-FU) and RT | NR (6yr) |
9 | Terada (2014) [5] | 49/M | Anal bleeding | Anal canal SRCC (< 2 cm) | AE1/3+ CK8+ CK19+ CEA+ CA19-9+ synaptophysin+ CDX2+ MUC1+ MUC2+ EMA+ CK7– CK20– CK5/6– MUC5AC– MUC6– CD56– NSE– chromogranin– vimentin– | T1N1M0, stage IIIA | Miles’ operation with LN dissection | Metastatic carcinomatosis and died (5 mo) |
10 | Kim et al. (2016) | 61/F | Erythematous perianal and vulvar skin for 3 yr, synchronous colon adenocarcinoma (0.2 cm) | Anal canal SRCC (4 cm), Pagetoid spread (8.2 cm) | pCEA+ CK20+ CK19+ MOC-31+ CDX2– CK7– HMB45– mucicarmine+ | T2N3M0, stage IIIB | Extended Miles’ operation and inguinal LN dissection, CTX (5-FU, MTC), RT (planned) | NR (2 mo) |
F, female; SRCC, signet ring cell carcinoma; pCEA, polyclonal carcinoembryonic antigen; mCEA, monoclonal carcinoembryonic antigen; PAS, periodic acid-Schiff; D-PAS, PAS diastase stain; 5-FU, 5-fluorouracil; EB, electron beam therapy; ASR, abdominosacral resection; CEA, carcinoembryonic antigen; ARF, acute renal failure; LN, lymph node; APR, abdominoperineal resection; CTX, chemotherapy; LV, leucovorin; NR, no recurrence; CA19-9, carbohydrate antigen 19-9; CK, cytokeratin; GCDFP-15, gross cystic disease fluid protein-15; RT, radiotherapy; M, male; mFOLFOX6, leucovorin, 5-FU, and oxaliplatin; FOLFIRI, irinotecan, 5-FU, and leucovorin; CR, complete remission; PET-CT, positron emission tomography-computed tomography; EMA, epithelial membrane antigen; NSE, neuron specific enolase; HMB-45, human melanoma black 45; MTC, mitomycin-C.
aThis case was diagnosed as Paget’s disease 15 years before the anal canal SRCC;
bThese articles were not available.
Clone, dilution, company | Anal canal signet ring cell carcinoma | Pagetoid spread of vulvar and perianal skin | |
---|---|---|---|
CK7 | OV-TL 12/30; 1:100 dilution; Dako, Glostrup, Denmark | – | – |
CK20 | Ks20.8; 1:100 dilution; Dako, Glostrup, Denmark | + | + |
CK19 | A53-B/A2.26; 1:200 dilution; Thermo Scientific, Fremont, USA | + | + |
CK5/6 | D5/16 B4; prediluted; Dako, Glostrup, Denmark | + weak | – |
EGFR | SP84; 1:30 dilution; Novocastra, Newcastle upon Tyne, UK | + | + |
CEA | Polyclonal; prediluted; Dako, Glostrup, Denmark | + | + |
MOC-31 | MOC-31; 1:70 dilution; Novocastra, Newcastle upon Tyne, UK | + | + |
CDX2 | AMT28; 1:50 dilution; Novocastra, Newcastle upon Tyne, UK | – | – |
S-100 protein | Polyclonal; 1:1,200 dilution; Dako, Glostrup, Denmark | – | – |
Synaptophysin | DAK-SYNAP; prediluted; Dako, Glostrup, Denmark | – | – |
Chromogranin | polyclonal; prediluted; Dako, Glostrup, Denmark | – | – |
CD56 | 123C3; prediluted; Dako, Glostrup, Denmark | – | – |
HMB45 | HMB45; prediluted; Dako, Glostrup, Denmark | – | – |
p53 | DO-7; 1:100 dilution; Dako, Glostrup, Denmark | + | + |
Case No. | Author | Age(yr)/Sex | Presenting symptom | Gross and histopathology | Immunohistochemistry | TNM at the initial evaluation | Treatment | Clinical outcome (follow-up period) |
---|---|---|---|---|---|---|---|---|
1 | Uchigasaki et al. (1992) [3] | 52/F | Anal ulcer and pruritus for 2 yr |
Anal canal SRCC progressed from adenocarcinoma in situ of anal glands or mucinous glands (1.5 cm), Pagetoid spread (7 cm) | pCEA+ mCEA+ mucicarmine+ PAS+ D-PAS-resistant | T1N3M0, stage IIIB | Topical 5-FU cream, EB, ASR | Recurrence with systemic metastasis and died (7 mo) |
2 | Morihisa et al. (1999) [7] |
75/F | Perianal erythema and erosion for 7 mo | Anal canal SRCC (size not described), Pagetoid spread (5 cm) | CEA+ mucicarmine+ PAS+ | N3M1, stage IV | Nephrostomy for ARF due to systemic metastasis | Systemic metastasis and died (4 mo) |
3 | Nagano et al. (1999) [8] | 46/F | Inguinal LN enlargement | Anal canal and rectal SRCC (3.5 cm), Pagetoid spread (7.5 cm) | Alcian blue+ PAS+ | T2N3M0, stage IIIB | APR, CTX (5-FU, LV) | NR (3 mo) |
4 | Naganuma et al. (2004) [9] | 85/F | Anal bleeding for 3 yr | Anal canal SRCC (unknown size of polyp, residual anal canal mass, 5 mm), Pagetoid spread (size not described) | CEA+ CA19-9+ CK20+ CK7– GCDFP-15– | N3M1, stage IV | Anal polypectomy with CTX (5-FU), RT | Systemic metastasis and died (25 mo) |
5 | Nishimura et al. (2004) [10] |
76/F | Anal erosion and etythema for 2 yr | Anal canal SRCC (size not described), Pagetoid spread (6 cm) | CK20+ GCDFP-15- | Not available |
APR, CTX (5-FU, cisplatin) | NR (5 mo) |
6 | Yoshitani et al. (2009) [11] | 50/M | Axillary and inguinal LN enlargement for 1 mo, erythematous perianal skin | Anal canal SRCC (size not precisely described; anal verge to dentate line), Pagetoid spread (size not described) | CK20+MUC-1+CK7- | N3M1, stage IV | CTX (bevacizumab/mFOLFOX6, FOLFIRI) | Alive with CR evaluated by PET-CT (6 mo) |
7 | Ikezawa et al. (2010) [12] | 53/M | Anal pruritus for 22 mo | Anal canal SRCC (1 cm), Pagetoid spread (2 cm) | pCEA+ CK20+ CK7– GCDFP-15– | T1N2M0, stage IIIB | APR, CTX (uracil-tegafur, LV, mFOLFOX6) | Recurrence with systemic metastasis and died (9 mo) |
8 | Ioannidis et al. (2012) [4] | 87/F | Anal discomfortness and pain for 8 mo | Anal canal SRCC (3 cm) | Not done | T2N0M0, stage II | Wide excision with chemotherapy (5-FU) and RT | NR (6yr) |
9 | Terada (2014) [5] | 49/M | Anal bleeding | Anal canal SRCC (< 2 cm) | AE1/3+ CK8+ CK19+ CEA+ CA19-9+ synaptophysin+ CDX2+ MUC1+ MUC2+ EMA+ CK7– CK20– CK5/6– MUC5AC– MUC6– CD56– NSE– chromogranin– vimentin– | T1N1M0, stage IIIA | Miles’ operation with LN dissection | Metastatic carcinomatosis and died (5 mo) |
10 | Kim et al. (2016) | 61/F | Erythematous perianal and vulvar skin for 3 yr, synchronous colon adenocarcinoma (0.2 cm) | Anal canal SRCC (4 cm), Pagetoid spread (8.2 cm) | pCEA+ CK20+ CK19+ MOC-31+ CDX2– CK7– HMB45– mucicarmine+ | T2N3M0, stage IIIB | Extended Miles’ operation and inguinal LN dissection, CTX (5-FU, MTC), RT (planned) | NR (2 mo) |
CK, cytokeratin; EGFR, epidermal growth factor receptor; CEA, carcinoembryonic antigen; CDX2, caudal-related homeobox gene nuclear transcription factor; HMB45, human melanoma black 45.
F, female; SRCC, signet ring cell carcinoma; pCEA, polyclonal carcinoembryonic antigen; mCEA, monoclonal carcinoembryonic antigen; PAS, periodic acid-Schiff; D-PAS, PAS diastase stain; 5-FU, 5-fluorouracil; EB, electron beam therapy; ASR, abdominosacral resection; CEA, carcinoembryonic antigen; ARF, acute renal failure; LN, lymph node; APR, abdominoperineal resection; CTX, chemotherapy; LV, leucovorin; NR, no recurrence; CA19-9, carbohydrate antigen 19-9; CK, cytokeratin; GCDFP-15, gross cystic disease fluid protein-15; RT, radiotherapy; M, male; mFOLFOX6, leucovorin, 5-FU, and oxaliplatin; FOLFIRI, irinotecan, 5-FU, and leucovorin; CR, complete remission; PET-CT, positron emission tomography-computed tomography; EMA, epithelial membrane antigen; NSE, neuron specific enolase; HMB-45, human melanoma black 45; MTC, mitomycin-C. This case was diagnosed as Paget’s disease 15 years before the anal canal SRCC; These articles were not available.